Targeting cytotoxic T lymphocytes for cancer immunotherapy
β Scribed by Maher, J; Davies, E T
- Book ID
- 109998189
- Publisher
- Nature Publishing Group
- Year
- 2004
- Tongue
- English
- Weight
- 157 KB
- Volume
- 91
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background and Objectives: We evaluated the clinical efficacy of adoptive immunotherapy using in vitro activated cytotoxic T lymphocytes (CTL) in the treatment of patients with advanced cancer. Methods: CTL were induced with the mixed lymphocyte and tumor cell culture method, in which lymphocyte
## Targeting cytotoxic T cells to antigen-specific B lymphocytes A recent development in immunomanipulation involves the targeting of cytotoxic T lymphocytes (CTL) to cell-bound antigens using bispecific antibodies. These antibodies have been engineered such that specificity is directed against th
## Abstract The prognosis of pancreatic cancer is extremely poor with a 5βyear survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic Tβlymphocyte (CTL) precursors reacting to peptide
## Abstract T lymphocytes are classified into 2 subsets based on their Tβcell receptor (TCR) expression. The vast majority of T cells expresses an Ξ±Ξ² TCR heterodimer. These Ξ±Ξ² T cells recognize antigenic peptides presented by MHC class I (for CD8^+^ T cells) or MHC class II molecules (for CD4^+^ T